Previous Posts
- The FDA and Drug Approval
- J&J Planned Profit from Risky, Unapproved Uses of ...
- What Are the Different Classes of Drug Recalls?
- What Is the Difference Between Class Action and Mu...
- First Lawsuit for Avandia Filed In Santa Clara Cou...
- Our Involvement in the Yaz®/Yasmin® Litigation
- What Is An FDA Black Box Warning?
- What Is a Drug Recall?
- First Lawsuit for Avandia Filed In Santa Clara Cou...
- Hazelnut Recall
Click Here to View
Our Other Site
Thursday, April 15, 2010
Avandia Given Positive Reviews Due to $$$$$?
And so the Avandia saga continues. A recent analysis of articles and reviews about the type 2 diabetes drug manufactured by drug giant, GlaxoSmithKline, indicates that experts who were paid by Glaxo consistently gave more positive reviews concerning the drug’s efficacy and safety than those not paid by Glaxo. Hundreds of studies have been performed in the last three years, many arriving at very different conclusions regarding this very popular drug.
The New England Journal of Medicine, in 2007, published an article indicating that the use of Avandia was "associated with a significant increase in the risk of heart attack." Shortly after the publication of this article, the FDA issued a black box warning and recommended that Glaxo take the dangerous drug off the market.
In response to the allegation that Avandia is receiving positive reviews based on money being paid to those reviewing the drug, Mary Anne Rhyne, Glaxo spokeswoman, said GSK "will disclose research payments made to health care professionals and their institutions" beginning next year; the disclosures will cover all research studies that began on January 1, 2010.
If you or a loved one has taken Avandia and has suffered adverse cardiac events because of it, please contact the defective drug attorneys at Schlichter, Bogard & Denton, serving Little Rock, Arkansas and all of the U.S., today to schedule a confidential consultation.
The New England Journal of Medicine, in 2007, published an article indicating that the use of Avandia was "associated with a significant increase in the risk of heart attack." Shortly after the publication of this article, the FDA issued a black box warning and recommended that Glaxo take the dangerous drug off the market.
In response to the allegation that Avandia is receiving positive reviews based on money being paid to those reviewing the drug, Mary Anne Rhyne, Glaxo spokeswoman, said GSK "will disclose research payments made to health care professionals and their institutions" beginning next year; the disclosures will cover all research studies that began on January 1, 2010.
If you or a loved one has taken Avandia and has suffered adverse cardiac events because of it, please contact the defective drug attorneys at Schlichter, Bogard & Denton, serving Little Rock, Arkansas and all of the U.S., today to schedule a confidential consultation.
posted by
Lynn
at
9:40 AM
<< Home